Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer.

Saved in:
Bibliographic Details
Title: Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer.
Authors: Pollin G; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Lomberk GA; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Mathison AJ; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Zimmermann MT; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Urrutia R; The RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Source: Journal of gastrointestinal oncology [J Gastrointest Oncol] 2024 Aug 31; Vol. 15 (4), pp. 1996-2001. Date of Electronic Publication: 2024 Aug 01.
Publication Type: Editorial; Comment
Journal Info: Publisher: AME Publishing Group Country of Publication: China NLM ID: 101557751 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2078-6891 (Print) Linking ISSN: 20786891 NLM ISO Abbreviation: J Gastrointest Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2078-6891
DOI:10.21037/jgo-24-326